Cor Vasa 2016, 58(6):788-794

Edoxaban v klinických studiích

Prof. MUDr. Jindřich ©pinar, CSc., FESC1, prof. MUDr. Jiří Vítovec, CSc., FESC2,*, prof. MUDr. Lenka ©pinarová, Ph.D., FESC2
1 Interní kardiologická klinika, LF MU a FN Brno, ICRC, Brno
2 I. interní kardioangiologická klinika, LF MU a FN u sv. Anny v Brně, ICRC, Brno

Edoxaban is a direct oral inhibitor of Xa factor with an anticoagulant and antiaggregant effect. The recommended dose is 60 mg perorally once daily. The effectivness and safety of the drug was confirmed in a large clinical trial ENGAGE AF-TIMI 48 with more than 21 000 patients. The ENSURE-AF trial has shown effectiveness and safety if compared with enoxaparin plus warfarin strategy in patients with electrical cardioversion for nonvalvular atrial fibrillation. The number of included patients was 2 199 and the primary effectiveness endpoints and safety endpoints were about 1% in both arms.

Keywords: Anticoagulation; Atrial fibrillation; Cardioversion; Edoxaban

Published: December 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©pinar J, Vítovec J, ©pinarová L. Edoxaban v klinických studiích. Cor Vasa. 2016;58(6):788-794.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. J. ©pinar, J. Vítovec, Antikoagulační léčba fibrilace síní, Acta medicinae 9 (2014) 18-23.
    2. J. ©pinar, J. Vítovec, L. ©pinarová, R. Lábrová, Rivaroxaban v léčbě fibrilace síní, Farmakoterapie 1 (2013) 6-12.
    3. J. Vítovec, J. ©pinar, Antikoagulační léčba u srdečního selhání a hypertenze. In: J. Widimský jr. Arteriální hypertenze - současné klinické trendy XIII, Praha: Triton, 2016, 157-162.
    4. SPC přípravku edoxaban 2016, 1-26.
    5. R.P. Giugliano, C.T. Ruff, E. Braunwald, et al., for the Engage TIMI 48 Investigators, Edoxaban versus warfarin in patiens with atrial fibrillation, New England Journal of Medicine 369 (2013) 2093-2104. Go to original source... Go to PubMed...
    6. J. ©pinar, J. Vítovec, Zasnouben se ąpičkovou kočkou aneb ENGAGED to TOPCAT, Kardiologická revue 15 (2013) 205-206.
    7. A. Goette, J.L. Merino, M. Ezekowitz, et al., Edoxaban versus enoxaparin / warfarin in subjects undergoing cardioversion of atrial fibrillation: the randomised (ENSURE-AF) study, Lancet 388 (2016) 1995-2003. Go to original source... Go to PubMed...
    8. Hokusai-VTE Investigators, H.R. Büller, H. Décousus, et al., Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism, New England Journal of Medicine 369 (2013) 1406-1415. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes